Ask AI
ProCE Banner Activity

Considerations in Selecting Therapy for Previously Treated CLL

Slideset
Download this slideset from a live symposium at ASH 2022 for expert perspectives on best practices in treating patients with relapsed/refractory CLL.

Released: December 09, 2022

Share

Provided by

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC
ProCE Banner

Supporters

This CE activity is supported through an educational grant from

AstraZeneca

BeiGene

Lilly

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Faculty Disclosure

Primary Author

Jennifer Woyach, MD

Director, Division of Hematology
Bertha Bouroncle MD and Andrew Pereny Chair of Medicine
Co-Director, Leukemia and Hematology Malignancies Research Program
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Jennifer Woyach, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Genentech, Janssen, Loxo, NewWave, Pharmacyclics; researcher: Schrödinger.